AR108630A1 - Virus vaccinia modificados genéticamente - Google Patents

Virus vaccinia modificados genéticamente

Info

Publication number
AR108630A1
AR108630A1 ARP170101463A ARP170101463A AR108630A1 AR 108630 A1 AR108630 A1 AR 108630A1 AR P170101463 A ARP170101463 A AR P170101463A AR P170101463 A ARP170101463 A AR P170101463A AR 108630 A1 AR108630 A1 AR 108630A1
Authority
AR
Argentina
Prior art keywords
vaccinia viruses
polynucleotide encoding
genetically modified
modified vaccinia
vaccinia virus
Prior art date
Application number
ARP170101463A
Other languages
English (en)
Original Assignee
Astellas Pharma Inc
Nat Univ Corp Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR108630(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc, Nat Univ Corp Tottori Univ filed Critical Astellas Pharma Inc
Publication of AR108630A1 publication Critical patent/AR108630A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente proporciona un virus vaccinia genéticamente recombinante eficaz para la prevención o el tratamiento del cáncer. Específicamente, la presente proporciona un virus vaccinia que comprende dos polinucleótidos, un polinucleótido que codifica IL-7 y un polinucleótido que codifica IL-12; un kit de combinación de dos virus vaccinia, un virus vaccinia que comprende un polinucleótido que codifica IL-7 y un virus vaccinia que comprende un polinucleótido que codifica IL-12; y el uso de los dos virus vaccinia en combinación. Composición farmacéutica y método de tratamiento para el cáncer.
ARP170101463A 2016-05-30 2017-05-29 Virus vaccinia modificados genéticamente AR108630A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016107481 2016-05-30

Publications (1)

Publication Number Publication Date
AR108630A1 true AR108630A1 (es) 2018-09-12

Family

ID=60477559

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101463A AR108630A1 (es) 2016-05-30 2017-05-29 Virus vaccinia modificados genéticamente

Country Status (28)

Country Link
EP (1) EP3480307B1 (es)
JP (1) JP6794442B2 (es)
KR (1) KR102357051B1 (es)
CN (1) CN109477089B (es)
AR (1) AR108630A1 (es)
AU (1) AU2017272721B2 (es)
BR (1) BR112018074881A2 (es)
CA (1) CA3026025A1 (es)
CO (1) CO2018013738A2 (es)
CY (1) CY1124314T1 (es)
DK (1) DK3480307T3 (es)
ES (1) ES2882538T3 (es)
HR (1) HRP20211145T1 (es)
HU (1) HUE054967T2 (es)
IL (1) IL263373B2 (es)
LT (1) LT3480307T (es)
MX (1) MX2018014779A (es)
MY (1) MY191091A (es)
PH (1) PH12018502548A1 (es)
PL (1) PL3480307T3 (es)
PT (1) PT3480307T (es)
RS (1) RS62077B1 (es)
RU (1) RU2757933C2 (es)
SG (1) SG11201810612TA (es)
SI (1) SI3480307T1 (es)
TW (1) TWI763673B (es)
UA (1) UA126380C2 (es)
WO (1) WO2017209053A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108686202A (zh) * 2017-04-06 2018-10-23 张晋宇 肿瘤免疫疗法
JP7274138B2 (ja) * 2017-11-30 2023-05-16 アステラス製薬株式会社 Ｓｃｒ欠失ワクシニアウイルス
CN113039277A (zh) 2018-01-05 2021-06-25 渥太华医院研究所 修饰的正痘病毒载体
AU2019351255A1 (en) 2018-09-26 2021-04-29 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
CN110205307A (zh) * 2019-01-07 2019-09-06 西安彤盛生物科技有限公司 去除vgf基因的重组天坛株溶瘤痘苗病毒及制备和应用
JPWO2020230785A1 (es) * 2019-05-14 2020-11-19
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
KR20220054819A (ko) * 2019-08-29 2022-05-03 아스테라스 세이야쿠 가부시키가이샤 유전자 변형 암용해 백시니아 바이러스 및 이의 사용 방법
US20230270847A1 (en) * 2020-02-18 2023-08-31 Vacdiagn Biotechnology Co., Ltd. Recombinant Viral Vector, Immunogenic Composition Comprising Same, and Uses
WO2022008519A1 (en) 2020-07-07 2022-01-13 BioNTech SE Therapeutic rna for hpv-positive cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
KR20240082387A (ko) 2021-10-06 2024-06-10 젠맵 에이/에스 암을 치료하기 위한 항 pd-1 항체와 조합된 pd-l1 및 cd137에 대한 다중특이적 결합제
IL311771A (en) 2021-10-06 2024-05-01 BioNTech SE Multispecific binding agents against PD-L1 and CD137 in combination
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
WO2024115725A1 (en) 2022-12-01 2024-06-06 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024181525A1 (ja) * 2023-03-01 2024-09-06 バイオコモ株式会社 抗がん剤、がん治療用医薬組成物、キット、及び活性化剤
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
JP2003512335A (ja) * 1999-10-18 2003-04-02 セント ビンセンツ ホスピタル アンド メディカル センター オブ ニューヨーク メラノーマワクチン並びにその製造方法及び使用方法
SG179291A1 (en) 2003-06-18 2012-04-27 Genelux Corp Modified recombinant vaccinia viruses and other microorganisms, uses thereof
EP1648233A4 (en) 2003-07-08 2006-08-23 Univ Arizona VACCINE VACCINE MUTANTS INSTEAD OF ONCOLYTIC AGENTS
EP1518932A1 (en) 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
ES2654303T3 (es) * 2007-05-04 2018-02-13 University Health Network Inmunoterapia de IL-12 contra el cáncer
CN103038343A (zh) * 2010-03-23 2013-04-10 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
JP5652830B2 (ja) * 2010-04-09 2015-01-14 国立大学法人 東京大学 マイクロｒｎａ制御組換えワクシニアウイルス及びその使用
WO2012151272A2 (en) * 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2758246C (en) * 2011-11-16 2013-02-12 Westport Power Inc. Method and apparatus for pumping fuel to a fuel injection system
CN105765062B (zh) * 2013-11-21 2020-12-11 国立大学法人鸟取大学 丝裂原活化蛋白激酶依赖性重组痘苗病毒(md-rvv)及其应用
GB201405834D0 (en) * 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus

Also Published As

Publication number Publication date
LT3480307T (lt) 2021-09-27
JP6794442B2 (ja) 2020-12-02
CN109477089A (zh) 2019-03-15
MX2018014779A (es) 2019-08-29
EP3480307A4 (en) 2020-01-01
JPWO2017209053A1 (ja) 2019-03-28
AU2017272721A1 (en) 2018-12-13
IL263373A (en) 2018-12-31
CO2018013738A2 (es) 2018-12-28
IL263373B1 (en) 2023-06-01
EP3480307B1 (en) 2021-06-23
BR112018074881A2 (pt) 2019-03-26
DK3480307T3 (da) 2021-07-12
MY191091A (en) 2022-05-30
TW201809270A (zh) 2018-03-16
PL3480307T3 (pl) 2021-11-08
SI3480307T1 (sl) 2021-09-30
RU2018146490A3 (es) 2020-11-17
HRP20211145T1 (hr) 2021-12-24
AU2017272721B2 (en) 2023-03-30
RS62077B1 (sr) 2021-07-30
KR20190014534A (ko) 2019-02-12
ES2882538T3 (es) 2021-12-02
CN109477089B (zh) 2022-05-24
CA3026025A1 (en) 2017-12-07
UA126380C2 (uk) 2022-09-28
SG11201810612TA (en) 2018-12-28
PH12018502548A1 (en) 2019-04-08
HUE054967T2 (hu) 2021-10-28
CY1124314T1 (el) 2022-07-22
KR102357051B1 (ko) 2022-02-03
EP3480307A1 (en) 2019-05-08
IL263373B2 (en) 2023-10-01
RU2757933C2 (ru) 2021-10-25
TWI763673B (zh) 2022-05-11
PT3480307T (pt) 2021-07-26
RU2018146490A (ru) 2020-07-10
WO2017209053A1 (ja) 2017-12-07

Similar Documents

Publication Publication Date Title
AR108630A1 (es) Virus vaccinia modificados genéticamente
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
CL2018002408A1 (es) Terapia de combinación con smc para el tratamiento de cáncer
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
CL2017003096A1 (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
HK1251459A1 (zh) 使用滅活的非複製型的修飾的痘苗病毒安卡拉(mva)作為實體腫瘤的單一免疫療法或與免疫檢查點阻斷劑的組合
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
AR109752A1 (es) Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis
BR112018008103A2 (pt) análogos de celastrol
CL2018002793A1 (es) Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
BR112017025998A2 (pt) inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
DK3463436T3 (da) Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling
ZA202102020B (en) Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
BR112019004906A2 (pt) combinação incluindo abx196 para o tratamento de câncer
CL2017001579A1 (es) Copolímeros de polidialilamina reticulados para el tratamiento de la diabetes de tipo 2
BR112017005993A2 (pt) derivados de peptídeo inovadores e usos dos mesmos
TR201722950A2 (tr) Koah tedavisinde yeni farmasötik bileşimler.
AR094912A1 (es) Vacuna contra el virus de la leucemia bovina
AR118512A1 (es) Uso de virus oncolíticos en la terapia neoadyuvante del cáncer